Introduction {#sec1}
============

Urinary tract infections (UTI) are among most common bacterial diseases both in community and hospital settings. Due to their high rate of frequency, recurrence, complications as well as increasing antimicrobial resistance, they pose a real challenge to medical professionals. Older people are more susceptible to UTI because their immune system is weaker, and comorbidities are often present ([@bib1]). *Escherichia coli* (*E. coli*) remains the predominant isolated uropathogen in Poland accounting for 80% of all uncomplicated infections ([@bib38]). However, in the presence of a urinary cathe ter, the spectrum of *E. coli* accounts for approximately 50% of total catheter-associated UTI (CAUTI), and other uropathogens become more prevalent ([@bib11]).

Of all hospital-associated UTI, 70--80% result from an indwelling urinary catheter, especially in older people, after surgical procedures and among patients staying in intensive care units ([@bib39]; [@bib32]; [@bib30]). Catheter use is also associated with noninfectious outcomes, including mechanical trauma, mobility impairment as well as urethral strictures ([@bib8]; [@bib18]). Additionally, prolonged catheterization increases the risk of biofilm formation in which uropathogens are difficult to treat with anti microbial agents ([@bib43]). Therefore, before deciding to catheterize the bladder it is important to estimate indications individually.

An optimal empirical therapy for UTI requires understanding of local epidemiology and antimicrobial susceptibility profiles. Uropathogens have developed resistance mechanisms to commonly prescribed anti biotics what limits treatment options of effective therapies. So, we conducted a study to describe clinical characteristics of patients with UTI, including CAUTI, as well as to determine etiology and susceptibility profiles of most common urinary isolates in different age groups.

Experimental {#sec2}
============

Materials and Methods {#sec3}
---------------------

A retrospective study was conducted on hospitalized adults from 1^st^ January 2013 to 31^st^ December 2015 in a Department of Internal Medicine and Nephrology with Dialysis Centre of Regional Hospital in southern Poland. During this period 4512 patients (2452 women and 2060 men) were hospitalized in our department in whom we diagnosed 498 cases of UTI. Among these cases, a group with CAUTI was distinguished. In the study, we made a systematic analysis of medical records of patients with diagnosed UTI.

UTI was diagnosed based on a positive result of a urine culture test with significant bacterial growth ≥ 10^5^ CFU/ml and a presence of at least one of the following symptoms: body temperature ≥ 37.5°C, dysuria, perineal pain, suprapubic pain or flank pain. Laboratory tests usually showed the elevated level of inflammatory markers and leucocyturia in urinalysis. According to the European Centre for Disease Prevention and Control ([@bib9]), diagnostic criteria for CAUTI included the maintenance of a catheter in the bladder for at least 7 days. The patients were also categorized by age as follows: 19--74 years (young old), 75--85 years (old old) and \> 85 years (longevity).

Urine for bacteriological examination was obtained from the middle stream but in catheterized patients after a catheter replacement with the hygiene and sterility principles preserved. All urine samples were inoculated in a Microbiology Department on Columbia agar with 5% sheep blood, Sabouarud agar and Chromogenic media. Inoculated agar plates were incubated aerobically at 35--37°C for 18--24 hours. Colonies were counted on the inoculated medium and multiplied by the loop volume to determine bacterial count. Bacterial identification was done by standard biochemical procedures, including Vitek 2 Compact system.

Antibiotic susceptibility testing (AST) as an *in vitro* assessment of activity of the antimicrobial drug was determined using the disc-diffusion and diffusion-gradient (E-test) methods. Zone diameters for individual antimicrobial agents were translated into susceptible, intermediate and resistant categories. According to the European Committee on Antimicrobial Susceptibility Testing (EUCAST), intermediate sensitivity strains were classified as resistant. A susceptibility level was calculated by dividing the number of sensitive strains to the antimicrobial agent by the total number of strains in relation to which the sensitivity to a particular antimicrobial agent was determined. Strains were tested against the following antibiotics: ampicillin, amoxicillin/clavulanic acid, piperacillin/tazobactam, amikacin, gentamicin, cefalexin, cefuroxime, cefotaxime, ceftazidime, cefepime, ciprofloxacin, norfloxacin, cotrimoxazole, imipenem and nitrofurantoin.

Because of *E. coli* predominance in the studied population, we analyzed susceptibility pattern only in reference to this uropathogen, including also division into age groups. The remaining microbes were not representative enough to be analyzed in this issue.

We accepted *p* \< 0.05 as the cut-off value for the level of statistical significance. The logistic regression test and *chi*-square test were used to compare independent variables. The calculations were carried out by the SPSS software (Statistical Package for the Social Sciences, STATISTICS 20, Armonk, NY, USA).

Results {#sec4}
=======

Among 4512 hospitalized patients, we recognized 498 cases of UTI (11.0%), of which 60 were CAUTI (1.3%). The mean age was 74.8 ± 14.6 years (ranging from 19 to 101 years) without differences between CAUTI and non-CAUTI population (76.2 ± 10.4 vs. 74.6 ± 15.0 years; *p* = 0.988). Hospitalization time was significantly longer in patients with CAUTI compared to those with non-CAUTI (13.63 ± 10.47 vs. 9.58 ± 6.66 days; *p* = 0.002).

Table [I](#tblI){ref-type="table"} presents the demographic and clinical characteristics of the studied population. Females showed much higher prevalence of the total UTI as 319 (64.1%), and in the non-CAUTI group than in the CAUTI group (67.6% vs. 38.3%; *p* \< 0.001). However, males were more common in the CAUTI group (61.7% vs. 32.4%; *p* \< 0.001). Patients who developed catheter-associated infections had more frequently genitourinary tumors (15.0% vs. 7.3%; *p* = 0.047) and urine stasis in kidneys (8.3% vs. 4.1%; *p* = 0.001). In addition, 10 men were after prostatectomy. No significance was found for other diseases and risk factors.

###### 

Characteristic of patients with UTI enrolled in the study.

![](pjm-67-4-517-t001)

  Characteristic             Total UTI n = 498 (100%)   CAUTI n = 60 (100%)   non-CAUTI n = 438 (100%)   OR (95% CI)   *p*-value           
  -------------------------- -------------------------- --------------------- -------------------------- ------------- ----------- ------- --------------------
  Gender:                    Male                       179                   35.9%                      37            61.7%       142     32.4%
  Female                     319                        64.1%                 23                         38.3%         296         67.6%   0.30 (0.17--0.52)
  Hypertension               263                        52.8%                 37                         61.7%         226         51.6%   1.51 (0.87--2.62)
  Heart failure              174                        34.9%                 23                         38.3%         141         32.2%   1.31 (0.75--2.29)
  Diabetes mellitus          190                        38.2%                 18                         30.0%         172         39.3%   0.72 (0.40--1.28)
  Urolithiasis               22                         4.4%                  1                          1.7%          21          4.8%    0.34 (0.04--2.55)
  Bronchopneumonia           9                          1.8%                  1                          1.7%          8           1.8%    0.91 (0.11--7.41)
  Malignancy (total)         80                         16.1%                 11                         18.3%         69          15.8%   1.34 (0.68--2.65)
  Genitourinary malignancy   41                         8.2%                  9                          15.0%         32          7.3%    2.24 (1.01--4.96)
  Prostatic hyperplasia      57                         11.4%                 10                         16.7%         47          10.7%   1.66 (0.79--3.50)
  Urine stasis in kidneys    23                         4.6%                  5                          8.3%          18          4.1%    4.34 (1.76--10.73)
  Percutaneous nephrostomy   8                          1.6%                  1                          1.7%          7           1.6 %   1.04 (0.13--8.63)
  Hemodialysis               20                         4.0%                  2                          3.3%          18          4.1%    0.80 (0.18--3.56)
  Immunotherapy              26                         5.2%                  4                          6.7%          22          5.0%    1.35 (0.45--4.06)

Data are expressed as number and percentage.

One patient may have several co-existing diseases

*E. coli* was the predominant isolated uropathogen in the studied population (72.9%). However, its occurence in the CAUTI group was significantly smaller compared to non-CAUTI group (61.7% vs. 74.4%; *p* = 0.039) (Table [II](#tblII){ref-type="table"}). The occurrence of other microbes in the CAUTI and non-CAUTI groups were much lower: *Proteus* sp. (10.0% vs. 5.5%; *p* = 0.174), *Staphylococcus* sp. (8.3% vs. 1.6%; *p* = 0.004), *Enterobacter* sp. (6.7% vs. 3.7%; *p* = 0.272), *Klebsiella* sp. (3.3% vs. 8.7%; *p* = 0.170) and *Enterococcus* sp. (3.3% vs. 2.0%; *p* = 0.532).

###### 

Microbial uropathogens isolated from the urine samples.

![](pjm-67-4-517-t002)

  Pathogen               Total UTI   CAUTI    non-CAUTI   OR (95% CI)   *p*-value                                 
  ---------------------- ----------- -------- ----------- ------------- ----------- -------- -------------------- -------
  *E. coli*              363         72.9%    37          61.7%         326         74.4%    0.55 (0.31--0.97)    0.039
  *Proteus* sp.          30          6.0%     6           10.0%         24          5.5%     1.92 (0.75--4.90)    0.174
  *Staphylococcus* sp.   12          2.4%     5           8.3%          7           1.6%     5.60 (1.72--18.24)   0.004
  *Enterobacter* sp.     20          4.0%     4           6.7%          16          3.7%     1.88 (0.61--5.84)    0.272
  *Klebsiella* sp.       40          8.0%     2           3.3%          38          8.7%     0.36 (0.09--1.54)    0.170
  *Enterococcus* sp.     11          2.2%     2           3.3%          9           2.0%     1.64 (0.35--7.80)    0.532
  Other                  22          4.4%     4           6.7%          18          4.1%     1.67 (0.54--5.10)    0.371
  Total                  498         100.0%   60          100.0%        438         100.0%   --                   --

Other pathogens:

*Pseudonomas* sp. (n = 6), *Morganella morganii* (n = 4), *Acinetobacter baumanii* (n = 3), *Serratia* sp. (n = 3), *Citrobacter* sp. (n = 2), *Raoultella planticola* (n = 1), *Salmonella* (n = 1), *Stenotrophomonas maltophilia* (n = 1), *Streptococcus agalactiae* (n = 1) ESBL-producing pathogens responsible for CAUTI: *E. coli* (n = 6), *Klebsiella* sp. (n = 2), *Enterobacter* sp. (n = 1) ESBL-producing pathogens responsible for non-CAUTI: *E. coli* (n = 23*)*, *Klebsiella* sp. (n = 12), *Enterobacter* sp. (n = 11), *Proteus* sp. (n = 4)

Production of extended-spectrum β-lactamases (ESBL) was found in 11.8% of total strains with the prevalence as follows: in the CAUTI (9/60; 15.0%) group and in the non-CAUTI (50/438; 11.4%) group. *Enterobacter* sp. were most frequently associated with ESBL production as 60.0% of all *Enterobacter* sp. isolates was positive, followed by *Klebsiella* sp. (35.0%).

Table [III](#tblIII){ref-type="table"} presents susceptibility profile of *E. coli* in the studied population to various antimicrobial agents. *E. coli* showed the highest prevalence of susceptibility to imipenem (100.0%), followed by gentamicin (91.0%), nitrofurantoin (89.4%), amikacin (88.2%), piperacillin/tazobactam (87.0%) and cephalosporins (79.7--89.5%). The prevalence of susceptibility was least to ampicillin (30.2%) and amoxicillin/clavulanic acid (49.9%). We also observed a fall in sensitivity level of *E. coli* to antibiotics among CAUTI patients compared to non-CAUTI individuals, with the significant differences in relation to piperacillin/tazobactam (68.4% vs. 88.8%; *p* = 0.017), amikacin (61.1% vs. 90.7%; *p* = 0.001), gentamicin (70.0% vs. 93.2%; *p* = 0.002), cefalexin (41.2% vs. 83.3%; *p* \< 0.001), cefotaxime (63.6% vs. 89.4%; *p* = 0.002), ceftazidime (61.9% vs. 85.6%; *p* = 0.008), cefepime (73.7% vs. 91.1%; *p* = 0.025), ciprofloxacin (54.1% vs. 72.2%; *p* = 0.024) and norfloxacin (40.5% vs. 62.5%; *p* = 0.011).

###### 

Susceptibility profile of *E. coli* isolates studied to various antimicrobial agents.

![](pjm-67-4-517-t003)

  Antibiotics                               Total UTI (n = 363)   CAUTI (n = 37)   non-CAUTI (n = 326)   OR (95% CI)   *p*-value                                
  ----------------------------------------- --------------------- ---------------- --------------------- ------------- ----------- -------- ------------------- ----------
  Beta-lactam antibacterials, penicylinns                                                                                                                       
  Ampicillin                                354                   30.2%            36                    19.4%         318         31.4%    0.53 (0.22--1.24)   0.143
  AM/CL                                     361                   49.9%            37                    43.2%         324         50.6%    0.74 (0.37--1.48)   0.397
  PIP/TZ                                    207                   87.0%            19                    68.4%         188         88.8%    0.27 (0.09--0.79)   0.017
  Aminoglycosides                                                                                                                                               
  Amikacin                                  211                   88.2%            18                    61.1%         193         90.7%    0.16 (0.06--0.47)   0.001
  Gentamicin                                211                   91.0%            20                    70.0%         191         93.2%    0.17 (0.06--0.52)   0.002
  Cephalosporins                                                                                                                                                
  Cefalexin                                 197                   79.7%            17                    41.2%         180         83.3%    0.14 (0.05--0.40)   \< 0.001
  Cefuroxime                                358                   85.8%            36                    75.0%         322         87.0%    0.45 (0.20--1.02)   0.057
  Cefotaxime                                238                   87.0%            22                    63.6%         216         89.4%    0.21 (0.08--0.55)   0.002
  Ceftazidime                               237                   83.5%            21                    61.9%         216         85.6%    0.27 (0.10--0.71)   0.008
  Cefepime                                  210                   89.5%            19                    73.7%         191         91.1%    0.27 (0.09--0.85)   0.025
  Antipseudomonal fluoroquinolones                                                                                                                              
  Ciprofloxacin                             361                   70.4%            37                    54.1%         324         72.2%    0.45 (0.23--0.90)   0.024
  Norfloxacin                               360                   60.3%            37                    40.5%         323         62.5%    0.41 (0.20--0.82)   0.011
  Folate pathway inhibitors                                                                                                                                     
  Cotrimoxazole                             358                   72.3%            36                    72.2%         322         72.4%    0.99 (0.46--2.14)   0.986
  Antipseudomonal carbapenems                                                                                                                                   
  Imipenem                                  179                   100.0%           18                    100.0%        161         100.0%   --                  --
  Nitrofuran derivatives                                                                                                                                        
  Nitrofurantoin                            357                   89.4%            37                    83.8%         320         90.0%    0.57 (0.22--1.48)   0.251

Abbrevations: Amoxicillin/clavulanic acid = AM/CL, Piperacillin/Tazobactam = PIP/TZ

n' -- number of all determinations for a given antibiotic; % susc. -- % susceptibility

An antimicrobial susceptibility profile of *E. coli* depending on age groups was summarized in Table [IV](#tblIV){ref-type="table"}. The youngest group constituted the reference for other groups. *E. coli* showed a similar susceptibility level to most antimicrobial agents between different age groups. In the longevity, *E. coli* demonstrated higher sensitivity to cephalosporins than in the young-old group, with significant differences relating to cefalexin (93.9% vs. 74.3%; *p* = 0.011), cefotaxime (96.7% vs. 81.9%; *p* = 0.017) and cefepime (98.2% vs. 84.9%; *p* = 0.033).

###### 

Susceptibility profile of *E. coli* (n = 363) isolated from patients of different age groups.
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  Antibiotics      19--74 years (n = 133)   75--85 years (n = 134)   \> 85 years (n = 96)   75--85 years vs. 19--74 years   \> 85 years vs. 19--74 years                                                             
  ---------------- ------------------------ ------------------------ ---------------------- ------------------------------- ------------------------------ -------- ------------------- ------- -------------------- -------
  Ampicillin       132                      31.1%                    130                    26.9%                           92                             33.7%    0.82 (0.48--1.40)   0.461   1.13 (0.64--1.99)    0.678
  AM/CL            133                      49.6%                    133                    51.1%                           95                             48.4%    1.06 (0.66--1.72)   0.806   0.95 (0.56--1.61)    0.858
  PIP/TZ           73                       86.3%                    80                     85.0%                           54                             90.7%    0.90 (0.36--2.23)   0.819   1.56 (0.50--4.85)    0.446
  Amikacin         74                       90.5%                    83                     81.9%                           54                             94.4%    0.47 (0.18--1.24)   0.127   1.78 (0.44--7.21)    0.422
  Gentamicin       72                       88.9%                    85                     89.4%                           54                             96.3%    1.06 (0.38--2.89)   0.916   3.25 (0.66--15.97)   0.147
  Cefalexin        70                       74.3%                    78                     75.6%                           49                             93.9%    1.07 (0.51--2.26)   0.849   5.31 (1.47--19.19)   0.011
  Cefuroxime       132                      85.6%                    133                    82.0%                           93                             91.4%    0.76 (0.40--1.47)   0.421   1.79 (0.75--4.28)    0.193
  Cefotaxime       83                       81.9%                    95                     85.3%                           60                             96.7%    1.28 (0.58--2.83)   0.548   6.40 (1.40--29.14)   0.017
  Ceftazidime      83                       80.7%                    94                     81.9%                           60                             90.0%    1.08 (0.51--2.31)   0.839   2.15 (0.79--5.87)    0.136
  Cefepime         73                       84.9%                    82                     87.8%                           55                             98.2%    1.28 (0.51--3.21)   0.602   9.58 (1.20--76.64)   0.033
  Ciprofloxacin    132                      72.0%                    134                    67.9%                           95                             71.6%    0.82 (0.49--1.39)   0.471   0.98 (0.55--1.76)    0.949
  Norfloxacin      133                      62.4%                    132                    59.1%                           95                             58.9%    0.87 (0.53--1.43)   0.581   0.86 (0.50--1.48)    0.598
  Cotrimoxazole    130                      74.6%                    133                    67.7%                           95                             75.8%    0.71 (0.42--1.22)   0.215   1.06 (0.58--1.97)    0.841
  Imipenem         57                       100.0%                   74                     100.0%                          48                             100.0%   --                  --      --                   --
  Nitrofurantoin   132                      91.7%                    131                    87.8%                           94                             88.3%    0.65 (0.29--1.47)   0.303   0.69 (0.28--1.66)    0.402

Abbrevations: Amoxicillin/clavulanic acid = AM/CL, Piperacillin/Tazobactam = PIP/TZ

n' -- number of all determinations for a given antibiotic; % susc. -- % susceptibility

Furthermore, we also carried out an analysis concerning *E. coli* sensitivity to antimicrobial agents in patients with CAUTI and non-CAUTI, according to age groups. No significant variations in drug susceptibility were noted among patients with catheter-associated infections between age groups. The only exception concerned the longevity group with non-CAUTI, in whom *E. coli* showed significantly higher prevalence of susceptibility than in the young old group, relating to cefalexin (*p* = 0.019) and cefotaxime (*p* = 0.034).

Discussion {#sec5}
==========

Urinary tract infection is emerging as an important community-acquired and nosocomial bacterial infection what was also confirmed by our 3-year analysis. It occurs on average in 1 per 10 of hospitalized patients and that was also presented in our previous study ([@bib26]).

In our study, UTI mainly concerned older people who constituted the majority, as evidenced by average age of the studied population. The proportion of older people is rising constantly from 11% in 2012 and it is supposed to reach 22% by 2050 ([@bib41]). Thus, challenges associated with infections in older population require specific assessment.

Urinary tract catheterization is one of the most common reason of bacteriuria caused by tendency of bacteria to adhere to artificial materials. It is believed that CAUTI occurs at a rate of 3--7% per day of catheterization and the incidences approach 100% within 30 days ([@bib25]). Among patients hospitalized in our department, CAUTI were diagnosed in 1.3% cases that was a slightly higher than in the study carried out in Australia -- 0.9% ([@bib13]). In another study, CAUTI were reported in 2.2% of hospitalized patients of the urological and orthopedic department ([@bib14]).

In the current study, CAUTI was significantly more frequent in men that was similar to the Korean report ([@bib22]). The authors, like in our study, analyzed the characteristics of CAUTI and non-CAUTI patients. They observed that CAUTI occurred significantly more often in patients with hypertension, those who used ventilators and after operations. In our analysis, CAUTI was more frequent in patients with genitourinary malignancy and urine stasis in kidneys. Patients with cancer have a greater tendency to acquire infections than general population due to cellular and humoral immune dysfunction, as well as complications of cancer therapy, including neutropenia or disruption of natural physical barriers ([@bib40]). Urinary tract obstruction provides an opportunity for bacteria to adhere to urothelium and infect patients. In such case, effective antibiotic therapy as well as an appropriate urological intervention is necessary to prevent recurrent UTI and septic complications.

The predominant uropathogen responsible for CAUTI in our study was *E. coli*, followed by *Proteus* sp. and *Staphylococcus* sp. In patients with non-CAUTI, apart from *E. coli*, we also frequently observed infections caused by *Klebsiella* sp. and *Proteus* sp. A lot of authors indicate a very similar bacterial flora ([@bib23]; [@bib20]; [@bib42]).

*E. coli* was the main etiological factor in both groups, however, its predominance was significantly smaller in catheter-associated infections. This is because CAUTI belong to complicated ones with higher rate of hospital-acquired infections, in which prevalence of the *E. coli* is not as high as in uncomplicated UTI ([@bib17]). In such a situation, other pathogens which are less commonly associated with UTI become more prevalent. Our study showed a significant increase of *Staphylococcus* sp. isolates in patients with CAUTI (*p* = 0.004). Recent studies highlighted that *Staphylococcus aureus* is a common problem associated with urinary catheterization, leading more often to bacteremia than other uropathogens ([@bib28]; [@bib5]).

*Proteus* sp. were the second most prevalent cause of CAUTI and occurred almost twice more often than in the non-CAUTI in this study. According to some reports, *Proteus mirabilis* is also supposed to be a frequent reason of CAUTI, especially in males, with a tendency to biofilm formation accounting for 17.9% of *Enterobacteraceae* family ([@bib19]; [@bib27]).

In the current study, *Klebsiella* sp. were the second common cause of non-CAUTI which is compatible with most publications ([@bib10]; [@bib2]). However, another study reported that *Pseudomonas* sp. were the second frequent isolated microorganisms responsible for 8.7% of total UTI ([@bib1]).

Antimicrobial resistance is now accepted as a major problem in public health and patient care. It is mainly associated with an abuse of antimicrobial agents and makes it difficult to choose a proper empirical treatment by medical practitioners, especially in cases of multidrug resistant strains ([@bib33]). Uropathogens developed resistance mechanisms of which the most common is ESBL. Organisms producing ESBL are clinically relevant and remain an important cause of failure of cephalosporins ([@bib6]). In this study, *Enterobacter* sp. and *Klebsiella* sp. were the most frequently ones associated with ESBL production of all these species, followed by *Proteus* sp. and *E. coli*. Similar results were also reported by other authors from Poland ([@bib35]). *E. coli* as the predominant uropathogen was responsible for ESBL production in 8.0% of total *E. coli* isolates being positive, similarly to the previous data from southern Poland ([@bib32]). For example, in France approximately 4.0% of *E. coli* isolates are ESBL producers, while in Mexico even 31.3% of *E. coli* isolates produce ESBL mechanism ([@bib12]; [@bib44]).

Susceptibility of *E. coli* in the studied population was highest to imipenem and gentamicin (\> 90.0%), and lowest to ampicillin as well as amoxicillin/clavulanic acid (\< 50.0%). This is similar to the reports from other countries with the exception of gentamicin which was a less effective drug ([@bib7]; [@bib24]). It may be since in our country gentamicin is rarely used as the first empiric choice for UTI treatment. Although, imipenem was the most effective drug, it should not be administrated as an empirical drug unless infection is life threatening, as carbapenems are considered drugs of last resort.

It is important to point out that the minimum susceptibility rate to support empirical treatment of UTI is 80% of all the strains of a specific uropathogen in a given region. According to these guidelines, the European Association of Urology (EAU) recommend cotrimoxazole as a first-line drug for empirical therapy in UTI ([@bib15]). In our study, 74.6% of *E. coli* isolates were susceptible to cotrimoxazole. Despite the fact that these values may vary among reports, the resistance rate of *E. coli* to cotrimoxazole in Europe tends to be above 20%, having also been reported higher than 30% ([@bib16]; [@bib37]). *E. coli* susceptibility to fluoroquinolones in the current study ranged from 60.3% (norfloxacin) to 70.4% (ciprofloxacin) which was similar to the rates observed in Brazil and Korea ([@bib34]; [@bib29]). Another study reported that *E. coli* was least sensitive to cephalosporins (7.0--34.0%) and fluoroquinolones (26.0--28.0%); however, a study was conducted on a population from low socioeconomic strata ([@bib21]). A good empirical choice seems to be nitrofurantoin but a study carried out in Poland showed a high proportion of resistance to nitrofurantoin among *E. coli* isolates ([@bib38]). Amikacin, as an infusion solution, may by administrated only in hospital settings. Cephalosporins also remain a good option for empirical treatment of UTI caused by *E. coli* because of relatively high sensitivity to this group of drugs and minor side effects. On the other hand, cephalosporins are commonly prescribed by medical professionals which causes a growing resistance to them among bacteria. Therefore, clinical practitioners as well as laboratory personnel should implement a program to detect and report resistant strains such as ESBL producing bacteria to control and limit the therapeutic failures.

Patients with CAUTI are a specific group in which treatment of the infection may by difficult due to a high resistance rate of uropathogens. In such a case, it is necessary to administer an adequate initial antimicrobial therapy according to local antimicrobial susceptibility situation ([@bib36]). Inadequate empirical antimicrobial therapy extends treatment contributing to various complications and transformation into a chronic illness. Our analysis confirmed that *E. coli* isolates were significantly less sensitive to most antibiotics in the CAUTI group compared to non-CAUTI group. Nitrofurantoin (83.8%) besides imipenem (100.0%), seemed to be an optimal choice in cases of catheter-associated infections caused by *E. coli*, contrary to ampicillin (19.4%). This result is compatible with another report ([@bib3]). However, other authors found amikacin (100.0%) and cefepime (100.0%) to be superior to nitrofurantoin (92.8%) in susceptibility rate what is incompatible with our analysis ([@bib31]).

Regardless of the age groups among the population analyzed in this study, *E. coli* showed sensitivity to most antibiotics, including: imipenem, nitrofurantoin, amikacin, gentamicin, piperacillin/tazobactam as well as cephalosporins. Moreover, in reference to our results, it may be helpful for medical practitioners to choose cefalexin, cefotaxime or cefepime in case of UTI caused by *E. coli* in the longevity group, because of their significantly higher susceptibility rate compared to young-old as well as old-old groups. Fluoroquinolones in our report turned out to have limited efficacy among patients with UTI, regardless of the age group. Thus, choosing them as first-line drugs in empiric therapy raises doubts and should be careful in admitted patients.

The results of this study can be used to construct a hospital formulary and internal procedure for antibiotics usage in case of UTI in a specific department. Our results can also be helpful for comparison between departments and hospitals interested in this issue.

There are some limitations to this study. First, we retrospectively collected data through electronic medical records. It was difficult to obtain all characteristics for analyzing risk factors such as previous antibiotics use and history of recurrent UTI due to unrecorded information. Second, this study was conducted only in a single center. Therefore, it is difficult to reflect the overall characteristics of our region. The current report suggests the need for further large-scale monitoring of epidemiology and susceptibility profiles of most common uropathogens causing UTI, including CAUTI, to improve the effectiveness of empirical treatment.

Conclusions {#sec6}
===========

The presented study showed considerable bacterial resistance to common empirically used antibiotics in case of CAUTI. *E. coli* susceptibility to fluoroquinolones was relatively low, which indicates the necessity of exclusion this group of drugs as first-line for the empirical treatment of UTI in our department. Nitrofurantoin as an alternative to carbapenems, can be used in empiric therapy of UTI, including CAUTI, regardless of the age group. Monitoring of susceptibility pattern is of great importance.
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